Mountain Valley MD Holdings hails Ivectosol lab study results on COVID-19 variants

Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) (FRA:20MP) says it aims to progress to Phase One human trials after a lab study of its Ivectosol technology showed positive antiviral effects on three coronavirus (COVID-19) variants. The BSL-4 study was the first of its kind ever conducted with human grade solubilized Ivermectin in the world, noted the biotech and was tested on the original B.1.1.7 variant, the South African B.1.351 variant and the P.1 Brazil variant. READ: Mountain Valley MD Holdings updates on "encouraging" progress in its pre-clinical trial portfolio Transgenic mice were modified with human ACE2 receptors and then dosed by aerosolization with COVID-19. Then, after five says, the mice were dosed with ascending therapeutic doses of Ivectosol as intramuscular injection. "This is the validation of our Ivectosol technology that we were looking for in its direct application to stop the replication of the targeted COVID-19 variants," said Dennis Hancock, CEO of Mountain Valley MD. "Knowing that Ivectosol has viral clearance effect on the three targeted variants we tested in the strictest lab environment in the world provides us with the confidence to pursue immediate human applications. We plan to progress quickly into Phase One human trials to support our vision for broad adoption and to also provide necessary and urgent support for the most disadvantaged communities globally." Mountain Valley said it would "immediately pursue" a combined pharmacokinetic and phase one human trial to verify the efficacy of Ivectosol sublingual wafers in COVID-19 infected patients.  The new human studies are anticipated to include the “triple-mutant India variant” B.1.617, and will determine overall efficacy, speed of viral clearance and safety levels of the Ivermectin drug in the firm's Ivectosol formulation, it said. Mountain Valley MD Holdings says it is building a world-class biotech and life sciences company centered around the implementation of its patented Quicksome oral drug formulation and delivery technologies. The company's solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration, making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity. Contact the author at giles@proactiveinvestors.com